advertisement

Bharat Biotech announces phase 3 results of Covaxin, says it demonstrates interim clinical efficacy of 81%

Noida,UPDATED: Mar 3, 2021 18:25 IST

Bharat Biotech has announced the results of phase 3 clinical trials of its Covid-19 vaccine candidate Covaxin. India's first Covid vaccine has demonstrated interim clinical efficacy of 81 per cent.

The phase 3 study of Covaxin involved 25,800 participants between 18-98 years of age.

Read more!
More videos from Coronavirus Outbreak

VIDEOS FROM OTHER SECTIONS

ProgrammeIndia First

LATEST VIDEOS

advertisement
advertisement